Although both anti-IL-12/23p40 and anti-IL-23p19 antibodies have been shown to alleviate experimental colitis to the same extent [25], there is no evidence suggesting a difference in the effects of these two antibodies in clinical practice. This evidence concerns the gene IL23A and colitis.